Type 1 diabetes (T1D) is an autoimmune disease where activation of the immune system causes the cells in the pancreas that produce insulin to be destroyed. The project aims to develop a drug that can significantly reduce the risk of hypo / hyperglycaemia and sequelae; a peptide drug that will help stabilize blood glucose levels in T1D patients. Patients will enjoy a better life through improved physical and mental health.
Menu